Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data
Cardiovascular Drugs and Therapy · 2023-02 · 37 (1) · 129-140
DOI: 10.1007/s10557-021-07255-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 08.10.2021. Verfasst von Osung Kwon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul,…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Anticholesteremic Agents, Atherosclerosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Korea.
Abstract (Originalsprache)
Purpose
To estimate the risk of recurrent cardiovascular events in a real-world population of very high-risk Korean patients with prior myocardial infarction (MI), ischemic stroke (IS), or symptomatic peripheral artery disease (sPAD), similar to the Further cardiovascular OUtcomes Research with proprotein convertase subtilisin–kexin type 9 Inhibition in subjects with Elevated Risk (FOURIER) trial population.
Methods
This retrospective study used the Asan Medical Center Heart Registry database built on electronic medical records (EMR) from 2000 to 2016. Patients with a history of clinically evident atherosclerotic cardiovascular disease (ASCVD) with multiple risk factors were followed up for 3 years. The primary endpoint was a composite of MI, stroke, hospitalization for unstable angina, coronary revascularization, and all-cause mortality.
Results
Among 15,820 patients, the 3-year cumulative incidence of the composite primary endpoint was 15.3% and the 3-year incidence rate was 5.7 (95% CI 5.5–5.9) per 100 person-years. At individual endpoints, the rates of deaths, MI, and IS were 0.4 (0.3–0.4), 0.9 (0.8–0.9), and 0.8 (0.7–0.9), respectively. The risk of the primary endpoint did not differ significantly between recipients of different intensities of statin therapy. Low-density lipoprotein cholesterol (LDL-C) goals were only achieved in 24.4% of patients during the first year of follow-up.
Conclusion
By analyzing EMR data representing routine practice in Korea, we found that patients with very high-risk ASCVD were at substantial risk of further cardiovascular events in 3 years. Given the observed risk of recurrent events with suboptimal lipid management by statin, additional treatment to control LDL-C might be necessary to reduce the burden of further cardiovascular events for very high-risk ASCVD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Health Innovation Big Data Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.
- Amgen Korea, Seoul, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. mdyhkim@amc.seoul.kr.
Förderung
- Amgen Korea
Zitieren
APA
Kwon, O., Na, W., Hur, J., Kim, J. H., Jun, T. J., Kang, H. J., Lee, H., & Kim, Y. H. (2023). Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data. Cardiovascular Drugs and Therapy, 37(1), 129-140. https://doi.org/10.1007/s10557-021-07255-2
Vancouver
Kwon O, Na W, Hur J, Kim JH, Jun TJ, Kang HJ, et al. Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data. Cardiovascular Drugs and Therapy. 2023;37(1):129-140. doi:10.1007/s10557-021-07255-2
BibTeX
@article{Kwon2023,
author = {Kwon, Osung and Na, Wonjun and Hur, Jaehee and Kim, Ju Hyeon and Jun, Tae Joon and Kang, Hee Jun and Lee, Hojoon and Kim, Young-Hak},
title = {Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data},
journal = {Cardiovascular Drugs and Therapy},
year = {2023},
volume = {37},
number = {1},
pages = {129--140},
doi = {10.1007/s10557-021-07255-2}
}
EUVIMED